Absolute Bioavailability of Vemurafenib in Patients With BRAFV600 Mutation–Positive Malignancies
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.773
Abstract: Vemurafenib is a BRAF kinase inhibitor indicated for the treatment of patients with BRAFV600 mutation–positive unresectable or metastatic melanoma and Erdheim‐Chester disease. This phase 1, open‐label, single‐arm study was designed to estimate absolute bioavailability of… read more here.
Keywords: mutation positive; bioavailability; absolute bioavailability; patients brafv600 ... See more keywords
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-0809
Abstract: Purpose: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients with previously untreated BRAFV600 mutation–positive advanced melanoma.… read more here.
Keywords: advanced melanoma; cobimetinib plus; plus vemurafenib; brafv600 mutation ... See more keywords